Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 10/20 | 0.66 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.66 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.66 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.66 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | SHBG | P04278 | 2/20 | 0.56 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.56 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | G6PD | P11413 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11042029 | 1.00 | CYP19A1 (0.66) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL8533582 | 0.86 | CYP19A1 (0.64) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL6254375 | 0.86 | CYP19A1 (0.64) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL11518397 | 0.86 | CYP19A1 (0.64) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL4585718 | 0.86 | CYP19A1 (0.64) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL10603778 | 0.81 | CYP19A1 (0.43) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL8677783 | 0.81 | CYP19A1 (0.58) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL868473 | 0.80 | CYP19A1 (1.00) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL22844489 | 0.80 | CYP19A1 (1.00) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL20787638 | 0.80 | CYP19A1 (0.80) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513509-A4 | NEBULIZER FORMULATIONS OF DEHYDROEPIANDROSTERONE AND METHODS OF TREATING ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE USING COMPOSTIONS THEREOF | EPIGENESIS PHARMACEUTICALS LLC (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2007055890-A2 | CO-ADMINISTRATION OF DEHYDROEPIANDROSTERONE (DHEA) CONGENERS AND OTHER ACTIVE AGENTS FOR TREATING CANCER | INFLABLOC PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-1033989-A4 | METHOD FOR REDUCING MAST CELL MEDIATED ALLERGIC REACTIONS | DOWELL TAD (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060217355-A1 | Co-administration of dehydroepiandrosterone (DHEA) congeners and other active agents for treating cancer | INFLABLOC PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | disclosed |
| US-20060154908-A1 | Co-administration of dehydroepiandrosterone (DHEA) congeners and other active agents for treating depression | INFLABLOC PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| US-20060122160-A1 | Co-administration of dehydroepiandrosterone (DHEA) congener with parthenolide for treating inflammation | INFLABLOC PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
| US-20060004076-A1 | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation | INFLABLOC PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
| EP-1589975-A2 | DEHYDROEPIANDROSTERONE (DHEA) CONGENERS FOR PREVENTION AND/OR TREATMENT OF ULCERS | Inflabloc Pharmaceuticals, Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1513509-A2 | NEBULIZER FORMULATIONS OF DEHYDROEPIANDROSTERONE AND METHODS OF TREATING ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE USING COMPOSTIONS THEREOF | Epigenesis Pharmaceuticals, Inc. (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2004058048-A2 | DEHYDROEPIANDROSTERONE (DHEA) CONGENERS FOR PREVENTION AND/OR TREATMENT OF ULCERS | INFLABLOC PHARMACEUTICALS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| US-6187767-B1 | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2001-02-13 | — | — | US | disclosed |
| US-6150348-A | ADMINISTERING A DEHYDROEPIANDROSTERONE (DHEA) DERIVATIVE TO A PATIENT SUFFERING FROM ADULT RESPIRATORY DISTRESS SYNDROME, PULMONARY HYPERTENSION | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2000-11-21 | — | — | US | disclosed |
| EP-1033989-A1 | METHOD FOR REDUCING MAST CELL MEDIATED ALLERGIC REACTIONS | University of Utah Research Foundation (US) | 2000-09-13 | — | — | EP | disclosed |
| US-5977095-A | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1999-11-02 | — | — | US | disclosed |
| US-5922701-A | Method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1999-07-13 | — | — | US | disclosed |
| WO-1999024039-A1 | METHOD FOR REDUCING MAST CELL MEDIATED ALLERGIC REACTIONS | PHARMADIGM, INC. (US) | 1999-05-20 | — | — | WO | disclosed |
| US-5859000-A | ADMINISTERING DEHYDROEPIANDROSTERONE DERIVATIVE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0067480-B1 | NOVEL MONO - AND BISQUATERNARY AMMONIUM DERIVATIVES OF 2-BETA, 16-BETA-DIAMINO-5-ALPHA-ANDROSTANE DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME | AKZO N.V. (NL) | 1984-11-28 | — | — | EP | disclosed |
| US-4447425-A | NEUROMUSCULAR BLOCKING AGENTS, MUSCLE RELAXANTS | AKZO N.V. (NL) | 1984-05-08 | — | — | US | disclosed |
| EP-0067480-A1 | Novel mono - and bisquaternary ammonium derivatives of 2-beta, 16-beta-diamino-5-alpha-androstane derivatives and pharmaceutical preparations containing same | AKZO N.V. (NL) | 1982-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004076-A1 | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation | CYP17A1, CYP21A2, SHBG | CYP19A1 9/4885AKR1B10 52/4885AKR1B1 44/4885 |
| US-20060122160-A1 | Co-administration of dehydroepiandrosterone (DHEA) congener with parthenolide for treating inflammation | CYP17A1, CYP21A2, HSD17B7 | CYP19A1 14/4885AKR1B10 107/4885AKR1B1 67/4885 |
| US-20060217355-A1 | Co-administration of dehydroepiandrosterone (DHEA) congeners and other active agents for treating cancer | SHBG, CYP21A2, HSD17B11 | CYP19A1 4/4885AKR1B10 86/4885AKR1B1 65/4885 |
| US-20060154908-A1 | Co-administration of dehydroepiandrosterone (DHEA) congeners and other active agents for treating depression | SHBG, HSD17B11, HSD17B2 | CYP19A1 15/4885AKR1B10 209/4885AKR1B1 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.